Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Resomelagon - Synact Pharma

Next Previous
Drug Profile

Resomelagon - Synact Pharma

Alternative Names: AP-1189

Latest Information Update: 15 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Synact Pharma
  • Class Anti-inflammatories; Antirheumatics; Hydrazines; Nitro compounds; Pyrroles; Small molecules
  • Mechanism of Action Melanocortin type 1 receptor agonists; Melanocortin type 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Membranous glomerulonephritis; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease
  • No development reported Inflammation

Most Recent Events

  • 08 Apr 2025 Federal University of Minas Gerais plans the phase IIa RESOVIR-2 trial for Dengue in Brazil (PO), in April 2025 (NCT06917001)
  • 14 Nov 2024 Efficacy and adverse events data from a phase II EXPAND trial in rheumatoid arthritis presented at the American College of Rheumatology Convergence (ACR-2024)
  • 01 Oct 2024 Phase-II clinical trials in Rheumatoid arthritis (Combination therapy, Treatment-naive) in USA (PO) (NCT06671054)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top